“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”
Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says
“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
Report details five instances of product hopping that collectively cost $4.7 billion annually.
“The main conclusion of Brill’s report is that Teva makes a significant contribution to the economies of the countries where it operates, via both direct and indirect employment.”
Based on MGA’s independent analysis, the Teva Global Economic Impact Report estimates Teva’s economic impact in 19 of the 60 countries in which Teva operates.
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.